IN THE CLAIMS

Please amend the claims as follows:

Claim 1. (Currently Amended): An injectable aqueous solution preparation having a pH from 2 to 5, the preparation comprising water and the following components (A) and (B):

(A) 7-ethyl-10-piperidinopiperidinocarbonyloxycamptothecin, and

(B) acetic acid and sodium acetate as the components that solubilize 7-ethyl-10-piperidinopiperidinocarbonyloxycamptothecin in the aqueous solution of the acetic acid and sodium acetate at a pH of 2 to 5.

Claim 2. (Previously Presented): The injectable aqueous solution preparation according to claim 1, wherein

the preparation further comprises component (C):

(C) (i) cyclodextrin,

(ii) ascorbic acid and sodium ascorbate,

(iii) propylene glycol, or

(iv) at least one compound selected from the group consisting of sodium hydrogen sulfite, sodium sulfite, potassium pyrosulfite, sodium erythorbate, sodium thioglycolate, sodium pyrosulfite, and α-thioglycerin.

Claim 3. (Cancelled)

Claim 4. (Previously Presented): The injectable aqueous solution preparation according to claim 1 or 2, wherein the aqueous solution preparation is an antitumor preparation.

Claim 5. (Cancelled)

Claim 6. (Previously Presented): The injectable aqueous solution preparation according to claim 1, wherein the content of the component (B) in terms of acetic acid is from 0.1 to 10% by weight of the injectable aqueous solution preparation.

Claim 7 (Previously Presented): The injectable aqueous solution preparation according to claim 1, wherein the content of acetic acid and sodium acetate in terms of acetic acid per 100 mg of 7-ethyl-10-piperidinopiperidinocarbonyloxycamptothecin in the injectable aqueous solution preparation is from 10 to 2000 mg.

Claim 8 (Previously Presented): The injectable aqueous solution preparation according to claim 2, comprising the cyclodextrin (i).

Claim 9 (Previously Presented): The injectable aqueous solution preparation according to claim 8, wherein the cyclodextrin (i) is an irreducible maltooligosaccharide comprising 6 to 12 glucose molecules which have been linked in a cycle by a α-1,4 glycosidic linkage.

Claim 10 (Previously Presented): The injectable aqueous solution preparation according to claim 8, wherein the cyclodextrin (i) is at least one selected from the group consisting of α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, and derivatives thereof, wherein the cyclodextrin derivatives are selected from the group consisting of maltosyl cyclodextrin, glucosyl cyclodextrin, dimethyl cyclodextrin, and hydroxypropyl cyclodextrin.

Claim 11 (Previously Presented): The injectable aqueous solution preparation according to claim 8, wherein the content of the cyclodextrin (i) is from 1 to 20% by weight of the injectable aqueous solution preparation.

Claim 12 (Previously Presented): The injectable aqueous solution preparation according to claim 8, wherein the content of the cyclodextrin (i) per 100 mg of 7-ethyl-10-piperidinopiperidinocarbonyloxycamptothecin in the injectable aqueous solution preparation is from 30 to 1000 mg.

Claim 13 (Previously Presented): The injectable aqueous solution preparation according to claim 8, wherein the content of the component (B) in terms of acetic acid is from 0.1 to 5.0% by weight of the injectable aqueous solution preparation.

Claim 14 (Previously Presented): The injectable aqueous solution preparation according to claim 2, comprising the ascorbic acid and sodium ascorbate (ii).

Claim 15 (Previously Presented): The injectable aqueous solution preparation according to claim 14, wherein the content of the ascorbic acid and the sodium ascorbate (ii) in terms of ascorbic acid is from 5 to 20% by weight of the injectable aqueous solution preparation.

Claim 16 (Previously Presented): The injectable aqueous solution preparation according to claim 14, wherein the content of the acetic acid and the sodium acetate in terms of the acetic acid is from 0.5 to 8% by weight of the injectable aqueous solution preparation.

Claim 17 (Previously Presented): The injectable aqueous solution preparation according to claim 14, wherein the acetic acid, the ascorbic acid, and their sodium salts are incorporated at the total content in terms of the respective acids from 0.1 to 20% by weight of the injectable aqueous solution preparation.

Claim 18 (Previously Presented): The injectable aqueous solution preparation according to claim 14, wherein the acetic acid, ascorbic acid, and their sodium salts are incorporated at the total content in terms of the respective acids from 500 to 2000 mg per 100 mg of 7-ethyl-10-piperidinopiperidinocarbonyloxycamptothecin in the injectable aqueous solution preparation.

Claim 19 (Previously Presented): The injectable aqueous solution preparation according to claim 2, comprising the propylene glycol (iii).

Claim 20 (Previously Presented): The injectable aqueous solution preparation according to claim 19, wherein the content of the propylene glycol (iii) is from 40 to 70% by weight of the injectable aqueous solution preparation.

Claim 21 (Previously Presented): The injectable aqueous solution preparation according to claim 19, wherein the propylene glycol (iii) is incorporated at the content from 1 to 4 g per 100 mg of 7-ethyl-10-piperidinopiperidinocarbonyloxycamptothecin in the injectable aqueous solution preparation.

Claim 22 (Previously Presented): The injectable aqueous solution preparation according to claim 19, wherein the content of the component (B) in terms of acetic acid is from 0.5 to 8% by weight of the injectable aqueous solution preparation.

Claim 23 (Previously Presented): The injectable aqueous solution preparation according to claim 2, comprising from 1 to 300 mg of the component (iv) per 100 mg of 7-ethyl-10-piperidinopiperidinocarbonyloxycamptothecin in the injectable aqueous solution preparation.

Claim 24 (Previously Presented): The injectable aqueous solution preparation according to claim 1, comprising from 1 to 50 mg/mL of 7-ethyl-10-piperidinopiperidinocarbonyloxycamptothecin in the injectable aqueous solution preparation.

Claim 25 (Previously Presented): The injectable aqueous solution preparation according to claim 1, which is an intravenous injectable aqueous solution preparation.